Vol 54, No 3 (2020)
Letter to the Editors
Published online: 2020-06-04
Does amantadine have a protective effect against COVID-19?
1
Abstract
Not available
References
- Zhu Na, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine. 2020; 382(8): 727–733.
- Rodon J, Noguera-Julian M, Erkizia I, et al. Search for SARS-CoV-2 inhibitors in currently approved drugs to tackle COVID-19 pandemia. .
- Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Multiple Sclerosis and Related Disorders. 2020; 42: 102163.
- Abreu G, Aguilar M, Covarrubias D, et al. Amantadine as a drug to mitigate the effects of COVID-19. Medical Hypotheses. 2020; 140: 109755.
- Tipton P, Wszolek Z. What can Parkinson’s disease teach us about COVID-19? Neurol Neurochir Pol. 2020; 54(2): 204–206.
- Cimolai N. Potentially repurposing adamantanes for COVID‐19. Journal of Medical Virology. 2020; 92(6): 531–532.
- Smieszek S, Przychodzen B, Polymeropoulos M. “Amantadine disrupts lysosomal gene expression; potential therapy for COVID19”. .
